Precision Medicine Market Size, Share, Trends | Opportunities, Demands and Growth Revenue by 2026 | Brandessence Market Research Report

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (Heraldkeepers) —
The Precision Medicine Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Precision Medicine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment; technological innovation and advancement , as well as growth of personal healthcare devices are major key factor which drives the Global Precision Medicine Market.

Get Sample Copy of This Premium Report https://brandessenceresearch.com/requestSample/PostId/55

**The sample pages of this report is immediately accessible on-demand.**

Top Precision Medicine companies:

key strategies followed by the top players operating in the precision medicine market are,

  • Abbott Laboratories
  • GE Healthcare
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Pfizer
  • Laboratories Corporation of America Holdings
  • Danaher Corporation
  • Biocrates Life Sciences AG
  • Nanostring Technologies
  • Intomics
  • Ferrer Incode
  • Eagle Genomics Ltd

Scope of Market Reports –

Precision medicine is often called as Personalized Medicine. It is used to describe how genetic information about a person’s disease is being used to diagnose or treat their disease. Precision Medicine refers to the modification of medical treatment to the individual characteristics of each patient. It does not exactly mean the manufacturing of drugs or medical devices that are unique to a patient, but the ability to categorize individuals into sub-populations that diverge in their susceptibility to a particular disease. Preventive or therapeutic interventions can then be focused on those who will benefit, sparing cost and side effects for those who will not. The main aim of government regulations is to make Precision Medicines more accepted and it is focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases.

The key objective of Cancergenomics is to improve personalized medicine through the DNA sequencing and analysis of patient tumors cells to find out new genetic mutation associated with specific cancers.

Genetic information has helped to increase the development and use of the newest cancer treatments like Chemotherapy, Radiation Therapy, Targeted Therapy and Precision Medicines. For example, the drug Imatinib was modified to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenousleukemia. Another example is the breast cancer drug Trastuzumab which works only for women whose tumors have a particular genetic profile calledHuman Epidermal Growth Factor Receptor 2(HER-2 positive). It is also found that lung cancer patients whose tumors are positive forEstimated Glomerular Filtration Rate (EGFR)mutations will respond to the drugs Gefitinib and Erlotinib which target this mutation. Conversely, colon cancer patients whose tumors have a mutation in a gene called KRAS (K-RAS) derive less benefit from the drugs Cetuximab and Panitumumab. The genomic information made by The Cancer Genome Atlas (TCGA) will boostthe research to develop similar treatment strategies for

Read more

Bioelectric Medicine Market Size, Share Report 2020 Shipments, Price, Revenue and Gross profit till 2025 With Impact of COVID-19

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Bioelectric Medicine Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Bioelectric Medicine Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Bioelectric Medicine market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Bioelectric Medicine industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16705148

In Regional Analysis, the Bioelectric Medicine market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Bioelectric Medicine market throughout the forecast length. The Bioelectric Medicine market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Bioelectric Medicine Market: – https://www.industryresearch.co/enquiry/request-covid19/16705148

Bioelectric Medicine market report provides in-depth data about company Profiles, Bioelectric Medicine launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Bioelectric Medicine market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Bioelectric Medicine market covered in report:

● Nevro ● Second Sight Medical Products ● Sonova Holding ● St. Jude Medical ● Medtronic ● Cochlear ● Electrocore ● Boston Scientific Corporation ● Livanova ● Biotronik

On the basis of types, the Bioelectric Medicine market from 2015 to 2025 is primarily split into:

● Implantable Cardioverter Defibrillators ● Cardiac Pacemakers ● Spinal Cord Stimulators ● Cochlear Implants ● Deep Brain Stimulators ● Transcutaneous Electrical Nerve Stimulators ● Vagus Nerve Stimulators ● Sacral Nerve Stimulators ● Retinal Implants ● Other Electrical Stimulators

On the basis of applications, the Bioelectric Medicine market from 2015 to 2025 covers:

● Hospitals ● Research Institutes ● Individual Users

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16705148

Bioelectric Medicine Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Bioelectric Medicine Market report describes present situation, historical background and future forecast. It Comprehensive data showing Bioelectric Medicine sale, consumption, trade statistics, and prices in the recent years are provided. The Bioelectric Medicine report indicates a wealth of information on Bioelectric Medicine vendors. Bioelectric Medicine Market forecast for next five years, including Market volumes

Read more

Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read more

Hair Transplant Market revenue to cross USD 40 Bn by 2026: Global Market Insights, Inc.

Some of the major hair transplant market players include Allergan Plc, Bernstein Medical, Bosley, GETFUE Hair Clinics Ltd., Hair Restoration BlackRockHRBR, Hair Club, Venus Concept (NeoGraft), Hairline International Hair and Skin Clinic, Hair Transplant Centre Turkey, Hair Transplants of Florida, Cole Instruments Inc. among others.

Selbyville, Delaware, Oct. 26, 2020 (GLOBE NEWSWIRE) —

According to latest report “Hair Transplant Market by Method (Follicular Unit Extraction [FUE], Follicular Unit Transplantation [FUT]), Product (Gel, Serum, Drugs, Multivitamins), Therapy (Platelet Rich Plasma, Stem Cell Therapy, Laser Therapy), Gender (Male, Female), Service Provider (Hospitals, Clinics, Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026”, by Global Market Insights, Inc., the market valuation of hair transplant will cross $40.1 billion by 2026.

Rise in number of people suffering from hair loss in Middle East and Africa region will act as a high impact rendering factor for the market growth. Increase in number of people suffering from hair loss in the Middle Eastern countries has resulted in more young men opting for hair transplant procedures. The major factors contributing to male pattern baldness are stress, genetics, illness or medication, climatic and water condition along with physiological factors such as malnutrition and ageing. According to the recently published article, around 60% of the male population in Middle East region is expected to experience hair loss in their lifetime, as compared to global average of 40%.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2810

Recent technological advancements, automation and cost-effectiveness of hair transplant procedure will drive the market value. Rising demand for single session hair restoration surgeries coupled with increase in awareness regarding physical appearance will further propel the market revenue.

Follicular unit extraction (FUE) segment in the hair transplant market valued more than USD 3,270 million in 2019 impelled by the rising number of men suffering from pattern baldness and growing adoption of the technologically advanced hair transplant methods by the surgeons. Furthermore, growing prevalence of alopecia cases coupled with increase in aging population base across the globe will fuel the segment growth in the coming years.

The hair transplant market for drugs segment is predicted to witness 25.5% growth rate from 2020 to 2026. The enhancement in alopecia treatment is mainly driven by the growing demand for hair loss treatment drugs that have shown higher effectiveness along with minimal side effects. In addition, increasing investment made by the leading players to develop novel hair transplant drugs will further boost the market expansion.

Platelet rich plasma (PRP) therapy in the hair transplant market accounted for USD 358 million in 2019. PRP is considered as one of the innovative and technological advanced hair transplant therapies for the patients suffering from hair thinning. PRP contains more than 20 growth factors that are considered exceptional for hair regrowth by stimulating the new hair cells and hence, this procedure will showcase higher adoption than other therapies.

Hair transplant market from male patient segment is estimated to expand at 25.8% CAGR through 2026 owing

Read more

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

  • Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of type 2 diabetes in July 2020 and a target launch is expected in fiscal year 20211; a milestone payment of EUR 4 million was received in Q3 2020 from Sumitomo Dainippon Pharma

  • Imeglimin Phase 3 TIMES results were presented at the 56th European Association for the Study of Diabetes (EASD) meeting; Phase 2b, Phase 3 TIMES results, and additional safety data were presented at the 63rd Annual Meeting of Japanese Diabetes Society (JDS)

  • PXL770 Phase 2a trial for the treatment of NASH met its primary efficacy endpoint and trial objectives, and it was observed to be safe and well tolerated

  • PXL770 profile supports development in NASH and also further evaluation for combination use, as well as utility of adenosine monophosphate-activated protein kinase (AMPK) activation in other chronic and rare metabolic diseases

  • PXL065 Phase 2 trial was initiated in biopsy-proven NASH patients in September 2020; streamlined development with a single Phase 2 trial given knowledge of pioglitazone, including data in NASH, and 505(b)(2) regulatory pathway, which offers the opportunity for an efficient and lower risk development program

  • As of September 30, 2020, cash and cash equivalents were EUR 41.5 million (USD 48.6 million)

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2020.

“During the third quarter, we continued to make significant progress and accomplished a number of important clinical and corporate objectives, including reporting positive results from a Phase 2a proof-of-concept trial for PXL770, demonstrating its potential in NASH. These results are the first human clinical assessment of a direct AMPK activator and support longer-term evaluation of important histological endpoints, such as inflammation and fibrosis, and exploring subpopulations for further differentiation. The data also demonstrate that AMPK activation may lead to broader utility for the treatment of other chronic and rare metabolic diseases. In addition, we initiated a streamlined Phase 2 trial for PXL065 in NASH and strengthened our cash position with non-dilutive funding from a milestone payment of EUR 4 million for the Imeglimin New Drug Application (NDA) submission in Japan and the recent PGE loan of EUR 6 million from the French government,” said Thomas Kuhn, CEO of Poxel.

“For the remainder of this year, we expect several upcoming milestones and events including finalization of the PXL770 Phase 2b clinical trial design, presentations for PXL770 and PXL065 at several scientific meetings as well as publishing results in peer-reviewed scientific journals and additional preclinical data related to our AMPK and deuterated-TZD platforms. Furthermore, our partner, Metavant, is in discussions with the U.S. Food and Drug Administration (FDA) regarding the Imeglimin Phase 3 program in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4,” added Thomas Kuhn,

Read more

Smart Fitness Market Outlook, Sales Revenue, Strategy to 2026

Smart fitness equipment are used for physical exercises that help in managing overall weight, improve physical stamina, and develop muscular strength. These devices are used to track information including sleep, steps, calories, heart rate, and other physical status, which further help in improving the overall fitness of the human body.
Rising awareness among people related to health and fitness is one of the major driving factors for growth of the global smart fitness market. The factor attributed to growth of the market is rising health issues such as obesity, diabetics, heart attack, which further increases demand for fitness equipment.

For instance, in 2013, according to the Institute for Health Metrics and Evaluation analysis, nearly 30% of the world population was suffering from obesity or overweight, globally. Moreover, according to the diabetics.org, the total number of people in the US suffering from diabetics was 7.2 million in 2014, and in 2015, 1.5 million new cases were reported which was 6.7% per 1,000 persons. Therefore, increasing awareness among people will proportionally demand for such fitness equipment, which will help them to track health related information such as heart rate, amount of calories burned and workout time. This is expected to further help to improve their overall fitness of the body, in turn aiding in growth of the global smart fitness market.

Furthermore, growing government initiative programs related to health awareness is another factor propelling growth of the market. For instance, in May 2004, in the 57th World Health Assembly (WHA) endorsed the World Health Organization ((WHO), Global Strategy on Diet, Physical Activity, and Health. The aim of this strategy is to promote and protect health by guiding at each individual, community, national, and global level such that it helps in reducing disease and death rates related to unhealthy diet and physical inactivity.

Browse More About the Market Study @
https://www.coherentmarketinsights.com/ongoing-insight/global-smart-fitness-market-1829

High price of smart fitness equipment is the major factor that limits growth of the market. This pushed start-up gyms & fitness centers and in-house users to buy second-hand equipment. Therefore, high prices of these equipment is a major factor hampering purchase of new equipment for commercial purposes. This is expected to negatively affect sales of new smart fitness equipment.

Global Smart Fitness Market: Segment Trends
On the basis of product type, the smart watch segment accounted for the largest market share in 2017 and is expected to retain its position during the forecasted period. This is owing to high demand for wireless health monitoring devices. For instance, according to the Coherent Market Insights' analysis, the total unit of smart watches sales in 2016 was US $ 36 million and it increased to US $ 76 million in 2017, globally. These smart watches carry out multiple functions such as real-time heart rate monitoring, fitness monitoring, tracking footsteps, tracking number of calories burnt, overall sleep statistics, tracking exercise training, and tracking of user's daily routine to offer valuable insights on their health. This further helps doctor to diagnose their patient's health remotely. This …

Read more
  • Partner links